NASDAQ:ELVN Enliven Therapeutics (ELVN) Stock Price, News & Analysis → $16T Crypto Plot From Elon Musk (From Crypto 101 Media) (Ad) Free ELVN Stock Alerts $21.70 -0.32 (-1.45%) (As of 06/14/2024 08:51 PM ET) Add Compare Share Share Today's Range$21.44▼$22.1050-Day Range$16.78▼$24.7052-Week Range$9.80▼$26.00Volume112,800 shsAverage Volume250,987 shsMarket Capitalization$1.02 billionP/E RatioN/ADividend YieldN/APrice Target$33.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Enliven Therapeutics alerts: Email Address Enliven Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.33 Rating ScoreUpside/Downside52.1% Upside$33.00 Price TargetShort InterestBearish20.28% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.61Based on 11 Articles This WeekInsider TradingSelling Shares$28.68 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.26) to ($2.74) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.56 out of 5 starsMedical Sector699th out of 913 stocksPharmaceutical Preparations Industry328th out of 429 stocks 3.7 Analyst's Opinion Consensus RatingEnliven Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnliven Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Enliven Therapeutics' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted20.28% of the float of Enliven Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnliven Therapeutics has a short interest ratio ("days to cover") of 15.4, which indicates bearish sentiment.Change versus previous monthShort interest in Enliven Therapeutics has recently increased by 2.64%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldEnliven Therapeutics does not currently pay a dividend.Dividend GrowthEnliven Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELVN. Previous Next 2.0 News and Social Media Coverage News SentimentEnliven Therapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Enliven Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for ELVN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,682,066.00 in company stock.Percentage Held by Insiders29.20% of the stock of Enliven Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enliven Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Enliven Therapeutics are expected to decrease in the coming year, from ($2.26) to ($2.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enliven Therapeutics is -11.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enliven Therapeutics is -11.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnliven Therapeutics has a P/B Ratio of 3.63. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Enliven Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad TradingTipsBuy these “two-bagger” stocksWe’ve put together something special for our subscribers — a free report on 5 stocks we believe could double in 2024. It’s straightforward, easy to understand, and most importantly, actionable.Download your free report today! About Enliven Therapeutics Stock (NASDAQ:ELVN)Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Read More ELVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELVN Stock News HeadlinesJune 11, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Sells $22,727.98 in StockJune 2, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells $98,515.00 in StockMay 21, 2024 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Rishi Gupta Sells 1,033,300 SharesMay 17, 2024 | insidertrades.comAnish Patel Sells 1,107 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockJune 12, 2024 | americanbankingnews.comEnliven Therapeutics (NASDAQ:ELVN) Upgraded to "Strong-Buy" at Baird R WJune 12, 2024 | americanbankingnews.comAnish Patel Sells 1,133 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockJune 12, 2024 | americanbankingnews.comEnliven Therapeutics (NASDAQ:ELVN) Now Covered by Analysts at Robert W. BairdJune 9, 2024 | americanbankingnews.comEnliven Therapeutics (NASDAQ:ELVN) Trading Up 8.2%May 29, 2024 | globenewswire.comEnliven Therapeutics to Present at Two Upcoming Investor ConferencesMay 29, 2024 | markets.businessinsider.comStrong Buy Rating for Enliven Therapeutics’ ELVN-001 Amid Favorable Market DynamicsMay 15, 2024 | finanznachrichten.deEnliven Therapeutics, Inc.: Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateMay 15, 2024 | investorplace.comELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q1 2024May 14, 2024 | globenewswire.comEnliven Therapeutics Reports First Quarter Financial Results and Provides a Business UpdateApril 28, 2024 | nasdaq.comCommit To Purchase Enliven Therapeutics At $10, Earn 11.2% Annualized Using OptionsApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth PotentialApril 26, 2024 | markets.businessinsider.comBuy Rating Affirmed: Enliven Therapeutics’ ELVN-001 Shows Market Potential and Efficacy in Resistant PatientsApril 19, 2024 | finance.yahoo.comMasterCraft Boat, SentinelOne, and More Stocks See Action From Activist InvestorsApril 18, 2024 | msn.comEnliven Therapeutics files to sell 6.43M shares for holdersApril 17, 2024 | msn.comEnliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02April 16, 2024 | investing.comEnliven Therapeutics CMO sells $501k in company stockApril 12, 2024 | investing.comEnliven reports promising Phase 1 data for leukemia drugApril 11, 2024 | markets.businessinsider.comStrong Buy Rating for Enliven Therapeutics’ ELVN-001 Following Outstanding Phase 1 Results and Market PotentialApril 11, 2024 | finance.yahoo.comEnliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead ProgramApril 11, 2024 | msn.comEnliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On ThursdayApril 11, 2024 | marketwatch.comEnliven Therapeutics Shares Hit 52-Week High After Positive Proof of Concept Data for Blood Cancer DrugSee More Headlines Receive ELVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/14/2024Today6/16/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ELVN CUSIPN/A CIK1672619 Webimaratx.com Phone617-927-9989FaxN/AEmployees46Year FoundedN/APrice Target and Rating Average Stock Price Target$33.00 High Stock Price Target$34.00 Low Stock Price Target$32.00 Potential Upside/Downside+52.1%Consensus RatingBuy Rating Score (0-4)3.33 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.83% Return on Assets-27.05% Debt Debt-to-Equity RatioN/A Current Ratio13.47 Quick Ratio13.47 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.97 per share Price / Book3.63Miscellaneous Outstanding Shares47,040,000Free Float33,302,000Market Cap$1.02 billion OptionableOptionable Beta1.11 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Samuel S. Kintz M.B.A. (Age 38)Co-Founder, CEO, Secretary & Director Comp: $597kDr. Helen Louise Collins M.D. (Age 61)Chief Medical Officer Comp: $558kDr. Joseph P. Lyssikatos Ph.D. (Age 59)Co-Founder, Chief Scientific Officer & Directors Dr. Galya D. Blachman Esq. (Age 47)Ph.D., Chief Legal Officer & Head of Business Development Key CompetitorsAvadel PharmaceuticalsNASDAQ:AVDLFulcrum TherapeuticsNASDAQ:FULCEditas MedicineNASDAQ:EDITDelcath SystemsNASDAQ:DCTHbluebird bioNASDAQ:BLUEView All CompetitorsInsiders & InstitutionsAnish PatelSold 1,133 sharesTotal: $22,727.98 ($20.06/share)Samuel KintzSold 12,000 sharesTotal: $278,160.00 ($23.18/share)Benjamin HohlSold 4,250 sharesTotal: $98,515.00 ($23.18/share)Janus Henderson Group PLCBought 305,397 shares on 5/16/2024Ownership: 1.519%Rishi GuptaSold 1,033,300 sharesTotal: $22.88 M ($22.14/share)View All Insider TransactionsView All Institutional Transactions ELVN Stock Analysis - Frequently Asked Questions Should I buy or sell Enliven Therapeutics stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Enliven Therapeutics in the last twelve months. There are currently 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ELVN shares. View ELVN analyst ratings or view top-rated stocks. What is Enliven Therapeutics' stock price target for 2024? 3 brokers have issued 1 year price objectives for Enliven Therapeutics' stock. Their ELVN share price targets range from $32.00 to $34.00. On average, they predict the company's stock price to reach $33.00 in the next twelve months. This suggests a possible upside of 52.1% from the stock's current price. View analysts price targets for ELVN or view top-rated stocks among Wall Street analysts. How have ELVN shares performed in 2024? Enliven Therapeutics' stock was trading at $13.84 at the start of the year. Since then, ELVN shares have increased by 56.8% and is now trading at $21.70. View the best growth stocks for 2024 here. When is Enliven Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our ELVN earnings forecast. How were Enliven Therapeutics' earnings last quarter? Enliven Therapeutics, Inc. (NASDAQ:ELVN) posted its quarterly earnings data on Tuesday, May, 14th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.04. What ETFs hold Enliven Therapeutics' stock? ETFs with the largest weight of Enliven Therapeutics (NASDAQ:ELVN) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR).Loncar China Biopharma ETF (CHNA). Who are Enliven Therapeutics' major shareholders? Enliven Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.52%), Janus Henderson Group PLC (1.52%), Baker BROS. Advisors LP (0.24%), Blackstone Inc. (0.05%), California State Teachers Retirement System (0.04%) and EntryPoint Capital LLC (0.02%). Insiders that own company stock include 5Am Partners Vi, Llc, Anish Patel, Benjamin Hohl, Joseph P Lyssikatos, Rahul D Ballal, Richard A Heyman, Rishi Gupta and Samuel Kintz. View institutional ownership trends. How do I buy shares of Enliven Therapeutics? Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELVN) was last updated on 6/17/2024 by MarketBeat.com Staff From Our PartnersTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored(Free Workshop) Advanced “bug-out bag” hacks!“Do you have a ‘bug-out bag’ (survival kit) ready to grab-and-go when a disaster or other crisis strikes?” ...Warrior Life | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the ...Crypto 101 Media | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.